|
CSRP2BP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.2994718068835E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.99119609689546E-11 |
| Normal-vs-Stage2 |
4.400000E-04 |
| Normal-vs-Stage3 |
2.08489999709016E-08 |
| Normal-vs-Stage4 |
3.61100038759332E-10 |
| Stage1-vs-Stage2 |
1.145220E-01 |
| Stage1-vs-Stage3 |
8.055600E-01 |
| Stage1-vs-Stage4 |
3.221700E-02 |
| Stage2-vs-Stage3 |
1.396430E-01 |
| Stage2-vs-Stage4 |
6.081400E-03 |
| Stage3-vs-Stage4 |
1.121210E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.15489864735719E-12 |
| Normal-vs-AfricanAmerican |
1.051720E-02 |
| Normal-vs-Asian |
1.07969999607604E-08 |
| Caucasian-vs-AfricanAmerican |
6.884200E-02 |
| Caucasian-vs-Asian |
4.279800E-01 |
| AfricanAmerican-vs-Asian |
1.950230E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.71140000451808E-08 |
| Normal-vs-Female |
3.23618909447987E-12 |
| Male-vs-Female |
6.775000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.21120019464161E-10 |
| Normal-vs-Age(41-60Yrs) |
6.51049991695629E-10 |
| Normal-vs-Age(61-80Yrs) |
1.31980000039889E-07 |
| Normal-vs-Age(81-100Yrs) |
7.226600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.387600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.825400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.563000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.310800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.674600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.947360E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.192300E-02 |
| Classical-VS-Follicular |
8.573600E-01 |
| Classical-VS-Other |
6.989600E-01 |
| Classical-VS-Normal |
1.31249999979488E-07 |
| Tall-VS-Follicular |
1.549400E-01 |
| Tall-VS-Other |
8.974600E-01 |
| Tall-VS-Normal |
4.23679999972393E-08 |
| Follicular-VS-Other |
6.523000E-01 |
| Follicular-VS-Normal |
7.00389999996887E-07 |
| Other-VS-Normal |
1.267910E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.33290003876152E-09 |
| Normal-vs-N1 |
1.62789781654737E-11 |
| N0-vs-N1 |
6.212000E-04 |
|
|
